Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03760029
Recruitment Status : Not yet recruiting
First Posted : November 30, 2018
Last Update Posted : June 17, 2019
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:

This is a multicenter, prospective, single cohort study designed to describe the natural history of DMD in Chinese male patients. A total of approximately 330 subjects will be enrolled with the target number of subjects in each group as below:

  • Group 1, subjects aged <6 years, 100 subjects;
  • Group 2, subjects aged >=6 years and <12 years, 180 subjects;
  • Group 3, subjects aged >=12 years, 50 subjects. Subjects will visit sites every 6 months. Each subject will be observed for at least 24 months. All subjects will remain enrolled until the study completion date, such that some will have data collected after Month 24. Subjects, who complete Visit 5/Month 24 at least 6 months prior to study completion, will be asked to complete an additional visit at Month 30.

Condition or disease Intervention/treatment Phase
Duchenne Muscular Dystrophy Other: Visit frequency Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 330 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A NATURAL HISTORY STUDY IN CHINESE MALE PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY
Estimated Study Start Date : June 2019
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2021


Arm Intervention/treatment
Study arm
All subjects in this study will be observed for 24-30 months.
Other: Visit frequency
All subjects need to visit sites more frequently than in routine clinical practice.




Primary Outcome Measures :
  1. Time to life altering clinical milestones due to DMD disease progression - failure to walk [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  2. Time to life altering clinical milestones due to DMD disease progression - failure to stand [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  3. Time to life altering clinical milestones due to DMD disease progression - failure to self feed [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  4. Change from Baseline in timed motor functions for ambulatory subjects - 4 stair climb [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  5. Change from Baseline in timed motor functions for ambulatory subjects - rise from floor (supine to stand) [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  6. Change from Baseline in timed motor functions for ambulatory subjects - 10 meter walk/run [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  7. Change from Baseline in timed motor functions for ambulatory subjects - 6 minute walk test [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  8. Change from Baseline in clinical evaluator determined scales - Expanded Hammersmith Functional Motor Scale [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  9. Change from Baseline in clinical evaluator determined scales - Northstar Ambulatory Assessment [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
    The Northstar Ambulatory Assessment will be performed in ambulatory children >=3 years old

  10. Change from Baseline in clinical evaluator determined scales - Performance of Upper Limb [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
    The Performance of Upper Limb will be administered in subjects >=5 years old.

  11. Change from Baseline in strength of muscle groups - knee extension [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  12. Change from Baseline in strength of muscle groups - elbow flexion [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  13. Change from Baseline in strength of muscle groups - elbow extension [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  14. Change from Baseline in strength of muscle groups - shoulder abduction. [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  15. Change from Baseline in pulmonary function tests - Forced Vital Capacity [ Time Frame: Change from baseline, 12, 24, 30 Months ]
  16. Change from Baseline in pulmonary function tests - Forced Expiratory Volume in one Second [ Time Frame: Change from baseline, 12, 24, 30 Months ]
  17. Change from Baseline in pulmonary function tests - Maximum Inspiratory Pressure [ Time Frame: Change from baseline, 12, 24, 30 Months ]
  18. Change from Baseline in pulmonary function tests - Maximum Expiratory Pressure [ Time Frame: Change from baseline, 12, 24, 30 Months ]
  19. Change from Baseline in pulmonary function tests - Peak cough flow [ Time Frame: Change from baseline, 12, 24, 30 Months ]
  20. Change from Baseline in range of motion (ROM) at bilateral ankles and elbows [ Time Frame: Change from baseline, 6, 12, 18, 24, 30 Months ]
  21. Change from Baseline in left ventricular ejection fraction (LVEF) [ Time Frame: Change from baseline, 12, 24, 30 Months ]
  22. Change from Baseline in Wechsler Intelligence Scale for Children (WISC) score in ambulatory subjects aged >=6 years to <=16 years [ Time Frame: Chang from baseline, 24 Months ]
    The WISC is individually administered intelligence test for children between ages of 6 and 16. It generates a Full Scale Intelligence Quotient.


Secondary Outcome Measures :
  1. Proportion of subjects with mutation of large deletion [ Time Frame: Baseline ]
  2. Proportion of subjects with mutation of large duplication [ Time Frame: Baseline ]
  3. Proportion of subjects with mutation of small insertion [ Time Frame: Baseline ]
  4. Proportion of subjects with mutation of small deletion [ Time Frame: Baseline ]
  5. Proportion of subjects with mutation of point mutation [ Time Frame: Baseline ]
  6. Proportion of subjects with mutations involving key high frequency mutation sites [ Time Frame: Baseline ]
  7. Change from Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) score [ Time Frame: Baseline, 12, 24, 30 Months ]
    The Pediatric Outcomes Data Collection Instrument is a patient-reported assessment of musculoskeletal health intended for use in children and adolescents.

  8. Change from Baseline in EuroQoL 5 Dimension 3 Level (EQ-5D-3L) [ Time Frame: Baseline, 12, 24, 30 Months ]
    The EQ-5D-3L is instrument measuring health-related quality of life for patients >=16 years old.

  9. Change from Baseline in EuroQoL 5 Dimension Youth (EQ-5D-Y) [ Time Frame: Baseline, 12, 24, 30 Months ]
    EQ-5D-Y is a generic instrument measuring health-related quality of life in children and adolescents younger than 16 years old.

  10. Change from Baseline in Healthcare Resource Utilization (HRU) score [ Time Frame: Baseline, 12, 24, 30 Months ]
    The result collection is based on the HRU questionnaire.

  11. Change from Baseline in Work Productivity and Activity Impairment Questionnaire adapted for Caregiving (WPAI:CG) impairment scores [ Time Frame: Baseline, 12, 24, 30 Months ]
    WPAI:CG will measure the impact of a subject with DMD on a caregiver's work productivity and regular activities. It will be administered as questionnaire.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Chinese male patients with any age, diagnosed with DMD. Diagnosis must be confirmed in subject's medical history and by genetic testing obtained during routine clinical care for diagnostic purposes as reported from an appropriate regulated laboratory using a clinically validated genetic test (genetic testing is not provided by the sponsor).
  2. Subjects who are >=4 years old must be receiving glucocorticosteroids for a minimum of 6 months prior to signing informed consent. There should be no significant change (<0.2 mg/kg) in dosage or dose regimen (not related to body weight change) for at least 3 months immediately prior to signing the informed consent. Subjects who are aged >4 years will be exempt from this requirement; those not taking GC will be eligible if the initiation of GC treatment in these subjects is considered inappropriate in the opinion of Investigators.

Exclusion Criteria:

  1. Any injury which may impact functional testing. Previous injuries must be fully healed prior to consenting. Prior lower limb fractures must be fully healed and at least 3 months from injury date.
  2. Presence or history of other musculoskeletal or neurologic disease or somatic disorder not related to DMD including pulmonary, cardiac, and cognitive diseases.
  3. Subjects >=4 years old who have not completed the recommended national immunization schedule and the varicella vaccination.
  4. Participation in other studies involving investigational drug(s) for a minimum of 90 days prior to signing the informed consent and/or during study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03760029


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT03760029     History of Changes
Other Study ID Numbers: C3391004
First Posted: November 30, 2018    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked